Welcome to our dedicated page for Renovorx news (Ticker: RNXT), a resource for investors and traders seeking the latest updates and insights on Renovorx stock.
RenovoRx, Inc. reports news on targeted oncology drug delivery, the commercialization of RenovoCath®, and clinical development of its TAMP™ therapy platform. The company is a life-sciences issuer developing localized cancer therapies and commercializing RenovoCath, a patented FDA-cleared drug-delivery device used for temporary vessel occlusion and chemotherapeutic drug infusion.
Recurring updates cover RenovoCath adoption at U.S. cancer centers, intellectual-property protection for the device, financing activity, financial results, and presentations of clinical or pharmacologic data. News also tracks IAG, the investigational intra-arterial gemcitabine product candidate delivered via RenovoCath, including disclosures tied to the TIGeR-PaC trial in locally advanced pancreatic cancer and orphan drug designations for pancreatic and bile duct cancer.
RenovoRx has announced the publication of pre-clinical studies demonstrating the efficacy of its Trans-Arterial Micro-Perfusion (TAMP) therapy platform.
The data, published in the Journal of Vascular Interventional Radiology, reveals a 100-fold increase in local tissue concentration of chemotherapy when using TAMP compared to conventional intravenous delivery.
TAMP aims to improve the safety and efficacy of oncology therapies by delivering drugs directly to solid tumors, potentially reducing systemic toxicity and widening the therapeutic window.
The studies were co-authored by experts from the Oregon Health and Science University, University of Pittsburgh Hillman Cancer Center, and RenovoRx.
The platform could address unmet needs in localized drug delivery, pending validation from ongoing Phase III clinical trials.
RenovoRx, a clinical-stage biopharmaceutical company (Nasdaq: RNXT), will take part in a fireside chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024. CEO Shaun Bagai will discuss the company's recent milestones, including raising $17.2 million through private placements. This funding will support RenovoRx's Phase III TIGeR-PaC clinical trial for its lead product, RenovoGem, aimed at treating locally advanced pancreatic cancer. The TIGeR-PaC's second interim analysis is anticipated by late 2024. The event will be moderated by Scott Henry, Managing Director at A.G.P.
RenovoRx, Inc. (RNXT) CEO Shaun R. Bagai will present at the Aegis Capital Virtual Conference on May 9, 2024. The company recently completed private placements raising $17.2 million. This funding will support the Phase III TIGeR-PaC clinical trial for RenovoGem™ in locally advanced pancreatic cancer. The second interim analysis is expected in late 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.